GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viveve Medical Inc (OTCPK:VIVE) » Definitions » Peter Lynch Fair Value

Viveve Medical (Viveve Medical) Peter Lynch Fair Value : $-66.25 (As of May. 23, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Viveve Medical Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Viveve Medical's PEG is 1. Viveve Medical's 5-Year TTM EBITDA Growth Rate is 25. Viveve Medical's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.65. Therefore, the Peter Lynch Fair Value for today is $-66.25.

As of today (2024-05-23), Viveve Medical's share price is $0.0003. Viveve Medical's Peter Lynch fair value is $-66.25. Therefore, Viveve Medical's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for Viveve Medical's Peter Lynch Fair Value or its related term are showing as below:



VIVE's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.7
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Viveve Medical Peter Lynch Fair Value Historical Data

The historical data trend for Viveve Medical's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viveve Medical Peter Lynch Fair Value Chart

Viveve Medical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Viveve Medical Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Viveve Medical's Peter Lynch Fair Value

For the Medical Devices subindustry, Viveve Medical's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viveve Medical's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viveve Medical's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Viveve Medical's Price-to-Peter-Lynch-Fair-Value falls into.



Viveve Medical Peter Lynch Fair Value Calculation

Viveve Medical's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 25 *-2.65
=-66.25

Viveve Medical's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.65.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Viveve Medical  (OTCPK:VIVE) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

Viveve Medical's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.0003/-66.25
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viveve Medical Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Viveve Medical's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Viveve Medical (Viveve Medical) Business Description

Traded in Other Exchanges
N/A
Address
345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112
Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.
Executives
Presnell Sharon Collins director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Wilmot B. Harkey 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Steven L Basta director 1875 S GRANT STREET SUITE 110, SAN MATEO CA 94402
Scott Durbin officer: Chief Financial Officer PO BOX 376, ANN ARBOR MI 48106
James G. Atkinson officer: CBO & President 150 COMMERCIAL STREET, SUNNYVALE CA 94086
Patricia Scheller director, officer: CEO and Director 150 COMMERCIAL STREET, SUNNYVALE CA 94086
Jon M Plexico director, 10 percent owner 16430 N SCOTTSDALE RD 450, SCOTTSDALE AZ 85254
Stonepine Capital Management, Llc director, 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Timothy P Lynch director, 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Daniel Janney director, 10 percent owner PO BOX 7414, JACKSON WY 83002